260 related articles for article (PubMed ID: 16888617)
1. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617
[TBL] [Abstract][Full Text] [Related]
2. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Int J Hematol; 2003 Apr; 77(3):232-8. PubMed ID: 12731665
[TBL] [Abstract][Full Text] [Related]
4. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
Bensinger WI
Best Pract Res Clin Haematol; 2007 Dec; 20(4):783-95. PubMed ID: 18070719
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation for multiple myeloma.
Bensinger WI; Maloney D; Storb R
Semin Hematol; 2001 Jul; 38(3):243-9. PubMed ID: 11486312
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity allogeneic stem cell transplantation in multiple myeloma.
Bensinger WI
Front Biosci; 2007 May; 12():4384-92. PubMed ID: 17485382
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation for multiple myeloma.
Bensinger WI
Biomed Pharmacother; 2002 May; 56(3):133-8. PubMed ID: 12046684
[TBL] [Abstract][Full Text] [Related]
8. The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma.
Bensinger WI
J Natl Compr Canc Netw; 2004 Jul; 2(4):371-8. PubMed ID: 19795599
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
12. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193
[TBL] [Abstract][Full Text] [Related]
13. Progress in allogeneic transplantation for multiple myeloma.
Gahrton G
Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
15. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
18. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
19. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.
Salit RB; Bishop MR
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):247-52. PubMed ID: 21658650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
